Epstein Barr Virus, or EBV, is a very common virus that many people get at some point in their life. It is part of the herpes virus family. Epstein-Barr virus (EBV) infects over 95% of the global population, establishing lifelong latency in B lymphocytes with periodic reactivation, particularly under conditions of immunosuppression or stress.The virus’s ability to evade immune surveillance and persist in host cells underlies its association with a spectrum of diseases, including infectious mononucleosis, chronic fatigue syndrome, and various malignancies. Despite its ubiquity and clinical impact, there are currently no FDA-approved antivirals or vaccines for EBV; management remains largely supportive, and investigational therapies have not yet translated into routine clinical practice.

• One of the most common human viruses, most people are infected at some point in their lives.

• Transmitted primarily through saliva (“the kissing disease”), but also through blood and organ transplants.
• Once you have EBV, the virus stays in your body for life in a resting (dormant) state. It can sometimes wake up again later, especially if your immune system is weakened.

Diseases Associated with EBV

1. Infectious Mononucleosis (“Mono”)
   • Classic presentation: fever, sore throat, swollen lymph nodes, and fatigue.
   • Enlarged spleen can occur with a risk during contact sports.
2. Chronic or Latent EBV Infection
   • Virus hides in B lymphocytes and can reactivate when the immune system is weakened.
3. Associated Conditions (rare, long-term risk)
   • Certain lymphomas such as Burkitt lymphoma or Hodgkin lymphoma
     Nasopharyngeal carcinoma
   • Post-transplant lymphoproliferative disease
   • Possible links with multiple sclerosis and chronic fatigue syndrome (still under study)
     

Diagnosis

• Blood tests (serologies like VCA IgM, VCA IgG, EBNA IgG) help determine if the infection is acute, past, or reactivated.
• Sometimes PCR is used for viral load, especially in immunocompromised patients.

Traditional Treatments

• Supportive only (rest, hydration, NSAIDs or acetaminophen).
• No specific antiviral therapy is routinely used
• Corticosteroids may be used in severe cases such as airway obstruction or massive tonsillar enlargement.
  Avoid contact sports if the spleen is enlarged to prevent rupture.

Conventional management of acute EBV infection remains supportive, emphasizing rest, hydration, and avoidance of contact sports due to the risk of splenic rupture. Corticosteroids may be considered for severe complications such as airway obstruction or hematologic involvement, but their routine use is discouraged due to uncertain long-term effects on host immunity and EBV-associated malignancy risk. Antiviral agents such as acyclovir have not demonstrated significant clinical benefit in randomized trials for uncomplicated EBV infection.

Functional Treatments

Functional medicine for EBV focuses on strengthening the body’s defenses so the immune system can keep the virus in check. This often involves nutrition, lifestyle, targeted supplementation, gut healing, and mitochondrial support, with additional options such as LDN, IV nutrient therapy, or NAD+ depending on the patient’s needs.

Functional medicine approaches have focused on nutritional and antioxidant therapies to modulate host immunity and viral activity. High-dose intravenous vitamin C (ascorbic acid) has demonstrated a reduction in EBV antibody levels and disease duration in patients with active infection, including those with chronic fatigue syndrome and mononucleosis. Plasma ascorbate levels inversely correlate with EBV VCA IgM titers, suggesting a potential role in suppressing viral replication and improving clinical outcomes. Additionally, N-acetylcysteine (NAC), an antioxidant precursor to glutathione, has been shown to ameliorate EBV-induced chronic inflammation in preclinical models by reducing leukocyte infiltration and tissue damage. NAC’s effect is mediated through restoration of redox balance and attenuation of the pro-inflammatory signaling induced by EBV latent membrane protein 1.  Experimental evidence suggests Glutathione may have a modulatory or protective role, warranting further investigation.Thiol-antioxidants such as glutathione can modulate EBV infection by altering the redox state of cell surface proteins, including the CD21 receptor, which is essential for EBV entry into B cells. In vitro studies demonstrate that glutathione and related compounds can reduce CD21 expression and thereby decrease cellular susceptibility to EBV infection, suggesting a potential mechanism for redox-dependent control of viral entry.. Additionally, glutathione peroxidase (GPX4), a key enzyme in the glutathione pathway, is implicated in the inhibition of EBV reactivation; TNF-α suppresses EBV reactivation through GPX4-mediated antioxidant activity, highlighting the importance of glutathione-dependent pathways in limiting viral lytic activation. Clinical observations indicate that decreased glutathione-related antioxidant activity is associated with EBV-positive oropharyngeal cancer, suggesting a possible protective role for glutathione in EBV-related disease states. Despite these mechanistic insights, there are no clinical guidelines for glutathione administration for the treatment of EBV infection. Vitamin D status also appears to modulate EBV antibody levels, with higher vitamin D associated with lower EBV early antigen IgG titers, supporting its immunomodulatory role.

But At What Doses:

High-dose intravenous vitamin C in the range of 7.5 g to 50 g per infusion has been found beneficial in patients with active Epstein-Barr virus infection, particularly those with chronic fatigue syndrome or mononucleosis. This dosing regimen was associated with reductions in EBV antibody levels and disease duration, with millimolar plasma ascorbate concentrations correlating with lower EBV VCA IgM titers.

N-acetylcysteine (NAC) has demonstrated benefit in preclinical models of EBV-induced chronic inflammation, with effective doses in animal studies typically ranging from 150 mg/kg to 300 mg/kg per day. In clinical practice for other viral and inflammatory conditions, oral NAC is commonly used at doses of 600 mg to 1800 mg per day, but specific dosing for EBV infection in humans has not been established in the medical literature. Intravenous NAC is FDA-approved for acetaminophen toxicity at a total dose of 300 mg/kg over 20–21 hours, but this regimen is not validated for EBV or other viral infections.Off-label use of intravenous NAC for other conditions (e.g., non-acetaminophen acute liver failure) has followed similar dosing, but there is no clinical evidence or consensus for its use or dosing in EBV infection.

Both agents are considered adjunctive and investigational for EBV infection, with vitamin C supported by clinical data and NAC by preclinical and mechanistic studies. No professional society guidelines currently recommend these therapies as standard of care for EBV infection.

Summary

EBV is a herpesvirus that causes mono and establishes lifelong latency. Most people recover without problems, but it can cause complications or contribute to cancers in rare cases.There is a clear need for large-scale clinical trials to evaluate the safety, efficacy, and integration of functional medicine approaches; including nutritional, antioxidant, and phytochemical therapies into EBV management. Current evidence is limited to observational studies, preclinical models, and in silico analyses, and robust clinical data are required to inform practice.

At Nervana Medical in Sandy, Utah, we believe patients deserve a clear understanding of both traditional and functional medicine approaches to Epstein-Barr virus (EBV). Conventional medicine focuses on managing symptoms and complications, while functional medicine emphasizes restoring immune balance, supporting mitochondrial health, and addressing underlying triggers that may drive viral reactivation. By explaining both pathways openly, we empower our patients to make informed choices about their care. Whether you are seeking standard antiviral support, integrative therapies, or a personalized combination, our goal is to help you regain energy, strengthen your immune system, and live your best life. Nervana Medical proudly serves patients in Sandy, Draper, South Jordan, Riverton, Herriman, Cottonwood Heights, Midvale, the greater Salt Lake City area as well as Arizona, Idaho, Montana, California and Nevada.

References

Bass, S., & Zook, N. (2013). Intravenous acetylcysteine for indications other than acetaminophen overdose. American Journal of Health-System Pharmacy, 70(17), 1496–1501. https://doi.org/10.2146/ajhp120645

Food and Drug Administration. (2025, April 30). ACETADOTE: FDA drug label. https://www.accessdata.fda.gov

Gao, X., Lampraki, E. M., Al-Khalidi, S., et al. (2017). N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation. PLOS ONE, 12(12), e0189167. https://doi.org/10.1371/journal.pone.0189167

Johns, M. M., & Hogikyan, N. D. (2000). Simultaneous vocal fold and tongue paresis secondary to Epstein-Barr virus infection. Archives of Otolaryngology–Head & Neck Surgery, 126(12), 1491–1494. https://doi.org/10.1001/archotol.126.12.1491

Kerr, J. R. (2019). Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. Journal of Clinical Pathology, 72(10), 651–658. https://doi.org/10.1136/jclinpath-2019-205822

Mikirova, N., & Hunninghake, R. (2014). Effect of high dose vitamin C on Epstein-Barr viral infection. Medical Science Monitor, 20, 725–732. https://doi.org/10.12659/MSM.890423

Nishinaka, Y., Nakamura, H., Okada, N., Okada, H., & Yodoi, J. (2001). Redox control of EBV infection: Prevention by thiol-dependent modulation of functional CD21/EBV receptor expression. Antioxidants & Redox Signaling, 3(6), 1075–1087. https://doi.org/10.1089/152308601317203585

Pennisi, R., Trischitta, P., Costa, M., et al. (2024). Update of natural products and their derivatives targeting Epstein-Barr infection. Viruses, 16(1), 124. https://doi.org/10.3390/v16010124

Pociupany, M., Snoeck, R., Dierickx, D., & Andrei, G. (2024). Treatment of Epstein-Barr virus infection in immunocompromised patients. Biochemical Pharmacology, 225, 116270. https://doi.org/10.1016/j.bcp.2024.116270

Rafailidis, P. I., Mavros, M. N., Kapaskelis, A., & Falagas, M. E. (2010). Antiviral treatment for severe EBV infections in apparently immunocompetent patients. Journal of Clinical Virology, 49(3), 151–157. https://doi.org/10.1016/j.jcv.2010.07.008

Santus, P., Danzo, F., Zuffi, A., et al. (2022). Oxidative stress and viral infections: Rationale, experiences, and perspectives on N-acetylcysteine. European Review for Medical and Pharmacological Sciences, 26(22), 8582–8590. https://doi.org/10.26355/eurrev_202211_30395

Strycharz-Dudziak, M., Kiełczykowska, M., Drop, B., et al. (2019). Total antioxidant status (TAS), superoxide dismutase (SOD), and glutathione peroxidase (GPx) in oropharyngeal cancer associated with EBV infection. Oxidative Medicine and Cellular Longevity, 2019, 5832410. https://doi.org/10.1155/2019/5832410

Zhang, Y., Wu, Y., Ding, B., et al. (2025). TNF-α inhibits Epstein-Barr virus reactivation through the GPX4 mediated glutathione pathway. Scientific Reports, 15(1), 16448. https://doi.org/10.1038/s41598-025-98679-5